Real-World Survival Outcomes Based on EGFR Mutation Status in Chinese Patients With Lung Adenocarcinoma After Complete Resection: Results From the ICAN Study

Xue‐Ning Yang; Hong‐Hong Yan; Jun Wang; Xiangyang Chu; Zhidong Liu; Yi Shen; Haitao Ma; Xiangning Fu; Jian Hu; Naikang Zhou; Yu Liu; Xinming Zhou; Jingsong Li; Kang Yang; Jian Li; Lin Xu; Siyu Wang; Qun Wang; Lunxu Liu; Shun Xu; Zhongyuan Chen; Hong-He Lou; Changli Wang; Ying Cheng; Si‐Yang Liu; Xu‐Chao Zhang; Wen‐Zhao Zhong; Yi‐Long Wu

doi:10.1016/j.jtocrr.2021.100257

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

INTRODUCTION: mutation status and adjuvant chemotherapy treatment. METHODS: mutation status, and postoperative stage were analyzed post hoc. RESULTS: mutation status across all postoperative stages. CONCLUSIONS: mutation status and postoperative stage.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Yang et al. (2021) studied this question.

synapsesocial.com/papers/6a01e0a61487eb4b96caf5c2 https://doi.org/10.1016/j.jtocrr.2021.100257

View Full Paper

Ask AI

Bookmark

Share

Real-World Survival Outcomes Based on EGFR Mutation Status in Chinese Patients With Lung Adenocarcinoma After Complete Resection: Results From the ICAN Study

Ask about this paper

Abstract

Discussion

Cite This Study

Real-World Survival Outcomes Based on EGFR Mutation Status in Chinese Patients With Lung Adenocarcinoma After Complete Resection: Results From the ICAN Study

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading